NASDAQ:COGT Cogent Biosciences Q2 2025 Earnings Report $11.40 -0.02 (-0.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.90 +0.50 (+4.43%) As of 08/1/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Cogent Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.54Beat/MissN/AOne Year Ago EPSN/ACogent Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACogent Biosciences Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time8:15AM ETConference Call ResourcesEarnings HistoryCompany Profile Cogent Biosciences Earnings HeadlinesNeedham Reaffirms Their Hold Rating on Cogent Biosciences (COGT)August 1 at 7:45 AM | theglobeandmail.comScotiabank Sticks to Its Buy Rating for Cogent Biosciences (COGT)August 1 at 2:08 AM | theglobeandmail.comMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space. While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded.August 2 at 2:00 AM | Stansberry Research (Ad)2 Biotech and 2 Tech Stocks Insiders Are Scooping Up NowJuly 23, 2025 | 247wallst.comJefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy RatingJuly 16, 2025 | msn.comCogent Biosciences Announces Closing of Upsized Public Offering of ...July 12, 2025 | morningstar.comMSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT), a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Upcoming Earnings Palantir Technologies (8/4/2025)Vertex Pharmaceuticals (8/4/2025)Axon Enterprise (8/4/2025)MercadoLibre (8/4/2025)Williams Companies (8/4/2025)ONEOK (8/4/2025)Simon Property Group (8/4/2025)Advanced Micro Devices (8/5/2025)Marriott International (8/5/2025)Amgen (8/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
